Investigating a role for eNAMPT-containing extracellular vesicles in mitigating age- and Alzheimer Disease-related cognitive decline
研究含有 eNAMPT 的细胞外囊泡在缓解年龄和阿尔茨海默病相关认知衰退中的作用
基本信息
- 批准号:10607376
- 负责人:
- 金额:$ 7.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AbateAcetylationAdipocytesAdipose tissueAgeAge-associated memory impairmentAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease patientAmyloidosisAnabolismBehaviorBehavioralBiologicalBiologyBrainC-terminalCell Culture TechniquesCell LineCellsCeramidesCharacteristicsCognitiveCognitive deficitsCritical PathwaysDataDeacetylaseDepositionDeteriorationEngineeringEnzymesFellowshipFunctional disorderFutureHippocampusHypothalamic structureImpaired cognitionIn VitroInjectionsKnock-in MouseKnock-outLabelLaboratoriesLeadershipLimbic SystemLocationLongevityMammalsMeasuresMediatingMembraneMemoryMentorshipMusNF-kappa BNeuronsNeurosciencesNicotinamide adenine dinucleotidePathologicPathologyPathway interactionsPeripheralPlasmaPlayPopulationPreparationProductionProteinsRoleSIRT1 geneSignal PathwaySirtuinsStainsSymptomsSynapsesTestingTherapeuticTissuesTrainingUniversitiesViralWashingtonage relatedagedanti agingbehavior measurementbrain cellcareercell typecellular targetingcognitive benefitscognitive functioncognitive reappraisalcollaborative environmentdensityeffective therapyeffectiveness testingempowermentextracellularextracellular vesiclesflexibilityhealthspanimprovedin vivoknock-downmorris water mazemouse modelnicotinamide phosphoribosyltransferasenoveloverexpressionrestorationsecondary endpointsmall hairpin RNAsuccesssynaptic functiontau Proteinstraffickingtranscriptome sequencingultra high resolutionuptake
项目摘要
PROJECT SUMMARY/ABSTRACT
The steady erosion of cognitive function is a hallmark of aging and markedly exacerbated in Alzheimer Disease
(AD). These deficits have no effective treatments. Depletion of nicotinamide adenine dinucleotide (NAD+) and
reduction of NAD+-dependent sirtuin activity in aging and AD have been well documented. Restoring NAD+ or
activating the sirtuin SIRT1 has induced abatement of aging symptoms including cognitive decline. However,
current NAD+ replenishment strategies are non-specific and the success of SIRT1 activation as an anti-aging
therapeutic may require tissue-specific activation and the concomitant restoration of NAD+. We have shown
previously that nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the major
mammalian NAD+ biosynthesis pathway, is contained in extracellular vesicles (EVs) and secreted to plasma.
Treatment of aged mice with plasma-derived EVs containing extracellular NAMPT (eNAMPT) extends mouse
lifespan and healthspan. Our preliminary data suggest that EV treatment can ameliorate cognitive dysfunction
and rescue age-related decreases in hippocampal CA1 synapse counts in 24-month-old mice. EVs are also
targeted to the brain and can increase NAD+ in cultured neurons. However, the tissue-specific EV targeting
mechanism as well as the implications for EV treatment in the context of AD-related cognitive decline remain
unknown. This study will test the hypothesis that EV-contained eNAMPT rescues age-related cognitive
dysfunction via activating SIRT1 in key neuronal populations and that leveraging this pathway can lessen AD-
associated cognitive decline. In Aim 1, cell culture-derived EVs will be utilized to test the necessity of eNAMPT
in the targeting and uptake of EVs both in vitro and in vivo. In Aim 2, the possibility that the cognitive benefits of
EV treatment occur through eNAMPT-mediated activation of SIRT1 will be evaluated. This determination will
be accomplished via EV treatment with and without EV-contained eNAMPT and with and without hippocampal
knockdown of Sirt1 by viral delivery of shRNA. Aim 3 will test the effectiveness of EVs in treating cognitive
deficits and pathological progression in a mouse model of AD. Therefore, this study has the potential to
elucidate a novel role for eNAMPT in facilitating both the cellular targeting of EVs and the efficacy of EVs in
rescuing age- and AD-related cognitive dysfunction. This project may also establish eNAMPT-containing EVs
as a viable biologic to treat cognitive deterioration in aging and AD. This fellowship proposal integrates the
NAD+ biology and aging expertise of sponsor Dr. Shin Imai with comprehensive training in behavioral
neuroscience, AD models, advanced synaptic analysis, EV engineering, and laboratory mentorship and
leadership. This training will be further empowered by the intellectually stimulating and highly collaborative
environment of Washington University in St. Louis. Thus, this fellowship will constitute ideal preparation for the
applicant’s career as the future leader of an academic laboratory.
项目摘要/摘要
认知功能的稳定侵蚀是衰老的标志,在阿尔茨海默氏病中明显恶化
(广告)。这些定义没有有效的治疗方法。烟酰胺腺苷二核苷酸(NAD+)和
已经有充分的文献记录了衰老和AD中NAD+依赖性的Sirtuin活性。还原nad+或
激活Sirtuin Sirt1已导致减轻衰老症状,包括认知能力下降。然而,
当前的NAD+补充策略是非特异性的,SIRT1激活作为抗衰老的成功
治疗可能需要组织特异性的激活和NAD+的伴随恢复。我们已经显示了
以前是烟酰胺磷酸贝糖基转移酶(NAMPT),这是主要限制酶
哺乳动物NAD+生物合成途径包含在细胞外蔬菜(EV)中,并分泌为血浆。
用含有细胞外NAMPT(ENAMPT)的血浆来源的EV对老年小鼠进行治疗,扩展了小鼠
寿命和健康范围。我们的初步数据表明,EV治疗可以改善认知功能障碍
在24个月大的小鼠中,海马CA1突触计数中与年龄相关的救援年龄下降。电动汽车也是
针对大脑,可以增加培养的神经元中的NAD+。但是,组织特异性的EV靶向
在与广告相关的认知下降的背景下,机制以及对EV治疗的影响仍然存在
未知。这项研究将检验以下假设,即持续的eNAMPT拯救了与年龄有关的认知
通过在关键神经元种群中激活SIRT1的功能障碍,并且利用此途径可以减少AD-
相关的认知下降。在AIM 1中,将利用细胞培养的衍生电动汽车来测试必要的ENAMPT
在体外和体内的电动汽车的靶向和摄取中。在AIM 2中,认知益处的可能性
将评估通过ENAMPT介导的SIRT1激活进行EV处理。这种决心将
可以通过有或没有EV的ENAMPT以及没有海马的EV处理来完成
通过病毒递送shRNA敲除SIRT1。 AIM 3将测试电动汽车在治疗认知方面的有效性
AD小鼠模型中的缺陷和病理进展。因此,这项研究有可能
阐明了ENAMPT在促进电动汽车的细胞靶向和电动汽车效率方面的新作用
营救年龄和广告相关的认知功能障碍。该项目还可能建立含ENAMP的EVS
作为治疗衰老和AD认知确定的可行生物学。该奖学金提案集成了
NAD+赞助商Shin Imai博士的生物学和老龄化专业知识以及行为方面的全面培训
神经科学,广告模型,先进的突触分析,EV工程和实验室心态以及
领导。智能刺激和高度协作的培训将进一步授权
圣路易斯华盛顿大学的环境。那,该奖学金将构成理想的准备
申请人作为学术实验室的未来领导者的职业生涯。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Vincent Lananna其他文献
Brian Vincent Lananna的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
脂肪酸β氧化介导ALKBH5乙酰化促进三阴性乳腺癌干细胞免疫逃逸的作用及机制研究
- 批准号:82373088
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
肠道菌群短链脂肪酸代谢物通过组蛋白去乙酰化酶HDAC2/ELK1通路调控模拟失重下成骨细胞分化和骨形成的机制研究
- 批准号:82302112
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
P53乙酰化调控P300/PPARγ促进乳腺癌细胞脂肪分化的机制研究
- 批准号:82303006
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
去乙酰化酶SIRT6调控肝脏Kupffer细胞参与非酒精性脂肪性肝炎的调控作用及机制研究
- 批准号:82300956
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ACSS2调控PGC1α启动子组蛋白乙酰化在糖尿病肾脏病肾小管上皮细胞脂肪酸氧化代谢中的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Metabolic regulation of muscle satellite cell homeostasis
肌肉卫星细胞稳态的代谢调节
- 批准号:
10591847 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
Regulation of brown fat fuel utilization by the malate-aspartate shuttle
苹果酸-天冬氨酸穿梭对棕色脂肪燃料利用的调节
- 批准号:
10712090 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment
PPARg 乙酰化抑制剂预防和治疗糖尿病的临床前验证
- 批准号:
10430186 - 财政年份:2021
- 资助金额:
$ 7.18万 - 项目类别:
Thioesterase-mediated lipotoxicity in liver and thermogenic adipose tissue
肝脏和产热脂肪组织中硫酯酶介导的脂毒性
- 批准号:
10614028 - 财政年份:2021
- 资助金额:
$ 7.18万 - 项目类别:
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment
PPARg 乙酰化抑制剂预防和治疗糖尿病的临床前验证
- 批准号:
10225150 - 财政年份:2021
- 资助金额:
$ 7.18万 - 项目类别: